Keyword Search Year None2022202120202019201820172016201520142013201220112010200920082007200620052004200320022001 09/28/22 Alkermes Announces Launch of 5th Annual Alkermes Pathways Research Awards® Program 09/20/22 Alkermes Showcases Research from Psychiatry Portfolio at Psych Congress 07/27/22 Alkermes plc Reports Second Quarter 2022 Financial Results 07/20/22 Alkermes to Report Second Quarter Financial Results on July 27, 2022 07/07/22 Alkermes Announces Results of Annual General Meeting of Shareholders 06/08/22 Alkermes to Participate in the Goldman Sachs Healthcare Conference 06/02/22 Alkermes Announces 2022 Alkermes Inspiration Grants® Program to Support Innovative Programs Focused on People Affected by Addiction, Serious Mental Illness or Cancer 06/01/22 Alkermes to Participate in the Jefferies Healthcare Conference 06/01/22 Alkermes Presents ARTISTRY-1 Data at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting 05/26/22 Alkermes Announces Continued Board Refreshment, Including the Appointment of Christopher I. Wright, M.D., Ph.D. to its Board of Directors 05/09/22 Alkermes Announces Four Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting 05/02/22 Alkermes to Highlight Data Related to Psychiatry Portfolio at Upcoming Scientific Conferences During Mental Health Awareness Month 04/27/22 Alkermes plc Reports First Quarter 2022 Financial Results 04/20/22 Alkermes to Report First Quarter Financial Results on April 27, 2022 04/19/22 Alkermes Commences Arbitration Related to License Agreements with Janssen Pharmaceutica 04/07/22 Alkermes Presents New Data From Psychiatry Portfolio at 2022 Congress of the Schizophrenia International Research Society 03/22/22 Alkermes to Participate in the Stifel 2022 CNS Days 03/01/22 Alkermes to Present Data on Nemvaleukin Alfa at the Society of Gynecologic Oncology 2022 Annual Meeting on Women's Cancer 02/17/22 Alkermes Presents New Nemvaleukin Alfa Monotherapy Data at the American Society of Clinical Oncology Genitourinary Cancers Symposium 02/16/22 Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2021 and Provides Financial Expectations for 2022 02/08/22 Alkermes Announces Positive Topline Results From ENLIGHTEN-Early Phase 3b Study of LYBALVI® in Patients Early in Illness 02/02/22 Alkermes to Report Fourth Quarter and Year-End 2021 Financial Results on Feb. 16, 2022 01/18/22 Alkermes to Present Data on Nemvaleukin Alfa at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium 01/06/22 New National Survey of People Living with Bipolar I Disorder Provides Insights Into Disease-Related Challenges and the Treatment Journey 01/05/22 Alkermes to Take Part in the 40th Annual J.P. Morgan Healthcare Conference
06/02/22 Alkermes Announces 2022 Alkermes Inspiration Grants® Program to Support Innovative Programs Focused on People Affected by Addiction, Serious Mental Illness or Cancer
06/01/22 Alkermes Presents ARTISTRY-1 Data at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
05/26/22 Alkermes Announces Continued Board Refreshment, Including the Appointment of Christopher I. Wright, M.D., Ph.D. to its Board of Directors
05/09/22 Alkermes Announces Four Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
05/02/22 Alkermes to Highlight Data Related to Psychiatry Portfolio at Upcoming Scientific Conferences During Mental Health Awareness Month
04/07/22 Alkermes Presents New Data From Psychiatry Portfolio at 2022 Congress of the Schizophrenia International Research Society
03/01/22 Alkermes to Present Data on Nemvaleukin Alfa at the Society of Gynecologic Oncology 2022 Annual Meeting on Women's Cancer
02/17/22 Alkermes Presents New Nemvaleukin Alfa Monotherapy Data at the American Society of Clinical Oncology Genitourinary Cancers Symposium
02/16/22 Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2021 and Provides Financial Expectations for 2022
02/08/22 Alkermes Announces Positive Topline Results From ENLIGHTEN-Early Phase 3b Study of LYBALVI® in Patients Early in Illness
01/18/22 Alkermes to Present Data on Nemvaleukin Alfa at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium
01/06/22 New National Survey of People Living with Bipolar I Disorder Provides Insights Into Disease-Related Challenges and the Treatment Journey
